By Vanda Felbab-Brown 

Over the past several decades, the U.S. opioid epidemic has spanned four phases:  Oversupply of prescription opioids in the 1990s.. A significant increase in heroin supply and use in the 2000s.  A supply-driven explosion of fentanyl use after 2012.  Most recently, polydrug use, with fentanyl mixed into/with all kinds of drugs. Since fentanyl entered the U.S. illegal drug market, more than a million people in the United States have died of opioid overdose. The costs of fentanyl use go beyond the tragic deaths and drug-use-related morbidity, however. In addition to having significant implications for public health and the economy, the fentanyl crisis intersects in many ways with U.S. foreign policy. U.S. overdose deaths began declining in 2023. But there is little certainty as to which domestic or foreign-policy interventions have been crucial drivers. The wider availability of overdose-reversal medication is fundamental, as is expanded access to evidence-based treatment. It is also possible that the Biden administration’s actions toward international supply from Mexico and China are contributing to this reduction in overdose deaths: since the start of 2024, China has become more active in suppressing the flow of precursor chemicals, and Mexican cartels, perhaps purposefully, are now trafficking a less lethal version of fentanyl. A wide array of policy measures as well as structural factors outside of policy control could be cumulatively and interactively reducing mortality. The fact that the declines in mortality are not uniform across U.S. ethnic, racial, and social groups or geographic areas suggests the importance of access to medication for overdose reversal and the treatment of opioid use disorder, as well as the influence of structural factors. There is strong bipartisan support for preserving access to medication-based treatments. But crucially, access depends on medical insurance coverage, such as that provided through Medicaid and the Affordable Care Act. There are strong ideological divides about the financing and structure of the U.S. insurance industry as well as other aspects of drug policy. On February 1, President Donald Trump imposed a 25% tariff on imports from Mexico and Canada and a 10% tariff on imports from China until each country stops the flow of fentanyl (as well as migrants, in the cases of Mexico and Canada).1 He gave all three countries a month-long reprieve before implementing the tariffs in March to see if they satisfied his counternarcotics demands. Canada adopted a robust package of anti-fentanyl measures. Mexico too tried to appease the United States through a set of law enforcement actions, though it held out on perhaps the most important form of cooperation—expanding the presence and mandates of U.S. law enforcement agents in Mexico to levels at least approaching those enjoyed during the Felipe Calderón administration. Unlike Mexico or Canada, China did not take any further counternarcotics actions and instead responded with counter-tariffs of its own, even as Trump threatened to add additional tariffs on imports from China of up to 60%.2 On March 4, 2025, Trump dismissed Canada’s and Mexico’s law enforcement actions as inadequate, implementing the 25% tariffs. He also added an additional 10% tariff on China, meaning the second Trump administration has now placed a 20% tariff on Chinese goods.3 Apart from increasing the cost of goods for U.S. customers and driving up inflation, these tariffs will have complex effects on anti-fentanyl cooperation. Any large U.S. tariffs on China will likely eviscerate Beijing’s cooperation with the United States, resetting the diplomatic clock  back to the bargaining of 2018 and noncooperation of 2021-2023. As crucial as it is to induce the government of Mexico to start robustly and systematically acting against Mexican criminal groups, whose power has grown enormously and threatens the Mexican state, Mexican society, and U.S. interests, Mexico has no capacity to halt the flow of fentanyl. Mixing the issues of migration and fentanyl risks Mexico appeasing the United States principally on migration while placating it with inadequate anti-fentanyl actions. Further, U.S. military action in Mexico, which has been threatened by Republican politicians close to Trump, would yield no sustained weakening of Mexican criminal groups or fentanyl flows. It would, however, poison the political atmosphere in Mexico and hinder its meaningful cooperation with the United States. Strong law enforcement cooperation with Canada is crucial. Canada has been facing law enforcement challenges, such as the expansion of Mexican and Asian organized crime groups and money laundering operations in Canada. But disregarding the domestic and collaborative law enforcement efforts Canada has put on the table is capricious. At home, Trump’s favored approach, which renews focus on imprisoning users and drug dealers, and dramatically toughening penalties for the latter, would be ineffective and counterproductive. And while providing treatment is very important, the dramatic effect of treatment modality on effectiveness cannot be overlooked. Approaches to treatment should be designed based on evidence, not ideology.

Washington, DC: Brookings Institute, 2025. 49p.

 By The United States Sentencing Commission

  More than 780,000 Americans died from a drug overdose in the last ten years. Overdose deaths have increased more than 300 percent from the level two decades ago. The number of such deaths has continued to increase in recent years, with the Centers for Disease Control reporting that 91,799 people died of drug overdoses in 2020, 106,699 in 2021, 107,941 in 2022, and 105,007 in 2023. Provisional data shows a recent decline in overdose deaths beginning in late 2023 and continuing into 2024. Overdoses remain one of the leading causes of deaths in adults in the United States. While fentanyl and fentanyl analogues, methamphetamine, cocaine, and heroin are the drugs most often involved in these deaths, synthetic opioids like fentanyl— which is up to 50 times more potent than heroin—contribute to nearly 70 percent of overdose deaths. In this report, the Commission examines all overdoses identified in drug trafficking cases reported to the Commission for fiscal years 2019 to 2023. One or more deaths occurred in more than three-quarters of these cases, while no deaths occurred in the remaining cases. The Commission is able to collect information about the overdoses reported in these cases through the sentencing documents the courts provide to the Commission in every case.8 Using that information, this report provides an analysis of the 1,340 individuals sentenced for a federal drug trafficking offense involving an overdose in fiscal years 2019 to 2023. In it, the Commission analyzes the demographic characteristics of these individuals, the offense conduct that occurred in the case, and how the courts sentenced these individuals—including the application of sentencing guideline provisions that provide for heightened base offense levels when the offense of conviction established that death or serious bodily injury resulting from an overdose occurred, or departures from the guideline range for death or physical injury, or how often courts varied from the guideline range for a similar reason. Additionally, in this report, the Commission provides the results of a special data collection project to explore the outcome of each overdose, the type of drug involved in the overdose, the victim’s knowledge of the drug they were taking, and the sentenced individual’s conduct during the offense.  

Washington, DC, USSC, 2025.   52p.

By Stacey Mckenna

Overdose deaths have skyrocketed across the United States in recent years, increasing by 622 percent between 2000 and 2020, with more than 112,000 lives lost in 2023. This crisis has been largely driven by the proliferation of potent synthetic opioids such as illicitly manufactured fentanyl, which is up to 50 times stronger than heroin.

The opioid antagonist, naloxone, is an especially important harm reduction tool in this landscape. Naloxone binds to opioid receptors in the brain, preventing other opioids, such as fentanyl or heroin, from binding to and activating them. The U.S. Food and Drug Administration (FDA) first approved the medication for the reversal of opioid overdoses in 1971. When administered in a timely manner, naloxone can restore breathing within minutes and successfully reverse 75 to 100 percent of overdoses.

Consequently, lawmakers and government agencies across the country have taken steps to improve access to naloxone. State legislatures have passed laws providing immunity to laypeople who administer the medication, authorized statewide standing orders to facilitate prescription-free pharmacy access, and purchased naloxone in bulk for direct distribution and to pass along to community-based organizations and first responders. Last year, the FDA approved intranasal naloxone products for over-the-counter sale for the first time.

However, with novel, increasingly potent synthetic opioids dominating the illicit supply, some medical experts worry that naloxone as we know it is simply not good enough anymore. In fact, in 2021, the FDA approved both higher-dose naloxone products and new, longer-lasting opioid antidotes, and some government agencies have begun purchasing these products for distribution in their communities.

This policy study aims to inform legislators and public health decision-makers about how high-dose naloxone fits into federal, state, and local efforts to combat the opioid overdose crisis. We examine the research on naloxone efficacy—in laboratory and medical settings and in the real world—and assess potential drawbacks associated with alternatives to standard-dose naloxone.

R Street Shorts No. 135 Washington, DC: R Street, 2024. 10p.